VAERS reports by lot

Merck HPV lot 1740U: VAERS reports

82 VAERS reports list lot 1740U as a Merck HPV vaccine, received between 2008-01-25 and 2015-02-04. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
82
Reports
48%
Marked serious
1
With a death outcome
26
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Neurological6120%
General / Systemic (non-local)6019%
Gastrointestinal5317%
Cardiac / Cardiovascular3210%
Injection-site / Local reaction3210%
Musculoskeletal186%
Respiratory165%
Allergic / Anaphylactic114%
Dermatological (non-injection-site)103%
Autoimmune / Immune-mediated72%
Thrombotic / Hematological52%
Reproductive / Menstrual52%
Psychiatric / Neuropsychiatric21%

Where reports came from

U.S. state of the reporter, where given (top 12).

Wisconsin7
Missouri4
New York4
Virginia4
Florida4
Georgia3
Ohio3
Michigan3
Kansas3
Indiana3
California3
North Carolina3

Reports by month received

2008-011
2008-024
2008-039
2008-049
2008-056
2008-068
2008-077
2008-089
2008-093
2008-105
2008-111
2008-121
2009-013
2009-021
2009-041
2009-051
2009-062
2009-072
2009-081
2009-091
2009-111
2010-012
2010-051
2010-091
2010-111
2015-021

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.